<DOC>
	<DOCNO>NCT01625741</DOCNO>
	<brief_summary>This study explore potential improve quality response obtain induction treatment Chronic Lymphocytic Leukemia ( CLL ) , give short intense consolidation schema use high-dose rituximab . Patients suboptimal response ( Minimal Residual Disease persistence ) induction select , well Minimal Residual Disease ( MRD ) relapse achieve MRD negativity .</brief_summary>
	<brief_title>Phase II Study High-Dose Rituximab High-Risk Chronic Lymphocytic Leukemia Patients Suboptimal Response After Induction Immunochemotherapy</brief_title>
	<detailed_description>This study reserve patient residual disease end therapy level Minimal Residual Disease ( MRD-positive either peripheral blood least 6 month last dose rituximab-containing immunochemotherapy bone marrow least 3 month last dose rituximab-containing immunochemotherapy ) . Patients achieve MRD eradication MRD relapse ( reappearance residual leukemic cell use 7/8-color flow cytometry peripheral blood bone marrow ) also eligible study . Rituximab give intravenously monthly dose 2000 mg four month ( total 4 dos 2000 mg ) , start within one month inform consent signature . The patient follow treatment period rituximab . A final evaluation do 3 month last dose rituximab .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Bcell Chronic Lymphocytic Leukemia define standard NCI criterion first line relapse &gt; 18 yearsold Presence Minimal Residual Disease ( MRD positivity ) Flow Cytometry criteria two clinical situation : 1 . Patients Complete Remission ( define standard criterion include Bone Marrow examination ) rituximabcontaining immunochemotherapy ( ICT ) , show persist MRD either Peripheral Blood least 6 month last dose rituximabcontaining immunochemotherapy Bone Marrow least 3 month last dose rituximabcontaining ICT 2 . Patients continuous CR show MRD relapse PB BM without clinical progression ( defined NCI ) time ICT ICT comprise : 1 . Rituximab combine fludarabine , without alkylating drug , without anthracycline ( ex : FludarabineRituximab , FludaCyclophsphamideRituximab , FCRMitoxantrone , Rbendamustine… ) 2 . At least 4 cycle Patients recover toxicity ICT POOR PROGNOSTIC FEATURES ( induction ICT ) define least one follow marker : stage C Binet , unmutated IgVH gene , 17p deletion , 11q deletion , Zap70 positivity , high CD38 , mutate IgVH gene VH321 usage In addition , patient 11q deletion and/or presence bulky lymph node prior induction therapy , absence profound lymph node response evaluation confirm CT scan CIRS ≤6 Absence significant geriatric syndrome and/or significant limitation instrumental activity daily live ( IADL ) Performance status ( ECOG ) &lt; 2 Neutrophils &gt; 1000/microL , platelet &gt; 100,000/microL Creatinine clearance &gt; 50 ml/min ( clearance reevaluate adequate hydration patient ) Patient 's write informed consent Less CR define standard criterion response ICT Ongoing active infection ( bacterial , viral fungal ) Known infection HIV Subjects serological evidence current past hepatitis B hepatitis C exposure exclude unless serological finding clearly due vaccination . Concomitant treatment steroid , immunosuppressive drug Uncontrolled autoimmune hemolytic anemia thrombocytopenia Transformation aggressive Bcell malignancy ( eg . diffuse large Bcell lymphoma , Hodgkin lymphoma ) Pregnancy , breast feeding , female patient childbearing potential male patient unwilling use adequate contraception Intolerance rituximab Concomitant severe disease ( uncompensated cardiac insufficiency , severe respiratory insufficiency… ) Severe hypogammaglobulinemia recurrent infection , unless patient receive substitutive IV immunoglobulins Transaminases ( AST , ALT ) &gt; 3 xULN Conjugated bilirubin &gt; 2 xULN Prior autologous stem cell transplantation le 12 month Prior allogeneic stem cell transplantation Central Nervous System involvement Any coexist medical psychological condition would preclude participation require study procedure Prior history malignancy , CLL , unless subject free disease &gt; 4 year . Exceptions include follow : basal cell carcinoma skin , squamous cell carcinoma skin , carcinoma situ cervix , carcinoma situ breast , incidental histologic find prostate cancer ( TNM stage T1a T1b ) Participation clinical study take investigational therapy would interfere study drug disease CLL , within 28 day prior initiate maintenance therapy .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>